Literature DB >> 17094425

Comparison of DNA sequencing and Roche Linear array in human papillomavirus (HPV) genotyping.

Laura Giuliani1, Anna Coletti, Kari Syrjänen, Cartesio Favalli, Marco Ciotti.   

Abstract

BACKGROUND: Human papillomavirus (HPV) is the etiological agent of cervical cancer. HPV genotyping is important to determine the presence of high-risk types. Recently, a new HPV genotyping method, the Roche Linear array genotyping test, was introduced and is compared here with a sequencing-based HPV genotyping system.
MATERIALS AND METHODS: A series of 102 women (age range 30-55 years) shown to be HPV DNA-positive by PCR were typed by sequencing and the Linear array genotyping assay.
RESULTS: The sequence analysis revealed the presence of 80 single high-risk types and 22 single low-risk types. With the Linear array, single infections were found in 46 cases, double infections in 37 cases, triple infections in 12 cases, and more than three in 6 cases. One case positive by sequencing gave a negative result by Linear array. Altogether, a concordant single genotype was found in 93 (91.2%) out of the 102 cases and the single-type concordance between the two assays was significant (Spearman rho = 0.849, p = 0.0001; intraclass correlation coefficient (ICC) (ICC = 0.924, 95% CI 0.888-0.949) (p = 0.0001). The majority of the disparate results were due to the detection of multiple types by the Linear array.
CONCLUSION: The Roche Linear array is a highly accurate assay for HPV genotyping. This is particularly true in the presence of multiple infections which DNA sequencing is unable to resolve.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17094425

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Reproducibility of linear array for human papillomavirus genotyping.

Authors:  Jill Koshiol; S Terence Dunn; Joan L Walker; Rosemary E Zuna; Mark Schiffman; Mark E Sherman; Michael A Gold; Richard A Allen; Roy Zhang; Sophia S Wang; Nicolas Wentzensen
Journal:  J Clin Microbiol       Date:  2012-11-28       Impact factor: 5.948

2.  Molecular genotyping of human papillomavirus l1 gene in low-risk and high-risk populations in Bangkok.

Authors:  Pornsawan Leaungwutiwong; Busara Bamrungsak; Akanitt Jittmittraphap; Pannamas Maneekan; Nathamon Kosoltanapiwat; Thareerat Kalambaheti; James F Kelley
Journal:  Sex Transm Dis       Date:  2015-04       Impact factor: 2.830

3.  Comparison of commercial hybridization and automated transcription-mediated amplification modalities for detection of high-risk human papillomavirus nucleic acid.

Authors:  Erik Munson; Lynn Kroeger; Sandra Balzer; Robert Amrhein; Kimber L Munson; Maureen Napierala; Richard Hudspeth; Patrick J Dillon
Journal:  J Clin Microbiol       Date:  2013-11-06       Impact factor: 5.948

4.  Prevalence of Human Papilloma Virus Types in Turkish and Albanian Women.

Authors:  Veysel Sabri Hancer; Murat Buyukdogan; Ilta Bylykbashi; Burcu Oksuz; Muradiye Acar
Journal:  J Cytol       Date:  2018 Oct-Dec       Impact factor: 1.000

5.  Transmission of human papillomavirus in heterosexual couples.

Authors:  Brenda Y Hernandez; Lynne R Wilkens; Xuemei Zhu; Pamela Thompson; Katharine McDuffie; Yurii B Shvetsov; Lori E Kamemoto; Jeffrey Killeen; Lily Ning; Marc T Goodman
Journal:  Emerg Infect Dis       Date:  2008-06       Impact factor: 6.883

6.  Prevalence of human papilloma virus (HPV) and its genotypes in cervical specimens of Egyptian women by linear array HPV genotyping test.

Authors:  Mohamed A Youssef; Lobna Abdelsalam; Reem Abdelhameed Harfoush; Iman Mamdouh Talaat; Eman Elkattan; Abeer Mohey; Rana M A Abdella; Marwa Salah Farhan; Hany Ahmed Foad; Abeer Mostafa Elsayed; Naglaa A Elkinaai; Doaa Ghaith; Mohamed Elsayed Rashed; Mohamed Abd-El Ghafar; Yasser Khamis; Ahmed N Hosni
Journal:  Infect Agent Cancer       Date:  2016-02-17       Impact factor: 2.965

Review 7.  HPV Associated Head and Neck Cancer.

Authors:  Tara Spence; Jeff Bruce; Kenneth W Yip; Fei-Fei Liu
Journal:  Cancers (Basel)       Date:  2016-08-05       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.